share_log

Earnings Troubles May Signal Larger Issues for SonoScape Medical (SZSE:300633) Shareholders

Earnings Troubles May Signal Larger Issues for SonoScape Medical (SZSE:300633) Shareholders

收益問題可能預示着SonoScape Medical (SZSE:300633)股東面臨更大的問題。
Simply Wall St ·  09/07 20:14

A lackluster earnings announcement from SonoScape Medical Corp. (SZSE:300633) last week didn't sink the stock price. We think that investors are worried about some weaknesses underlying the earnings.

SonoScape Medical Corp.(深圳證券交易所代碼:300633)上週公佈的業績乏善可陳,但這並沒有使股價下跌。我們認爲,投資者擔心收益背後的一些弱點。

big
SZSE:300633 Earnings and Revenue History September 8th 2024
SZSE: 300633 收益和收入歷史記錄 2024 年 9 月 8 日

The Impact Of Unusual Items On Profit

不尋常物品對利潤的影響

Importantly, our data indicates that SonoScape Medical's profit received a boost of CN¥33m in unusual items, over the last year. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. Which is hardly surprising, given the name. If SonoScape Medical doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.

重要的是,我們的數據表明,與去年相比,SonoScape Medical的不尋常項目利潤增加了3300萬元人民幣。雖然獲得更高的利潤總是件好事,但來自不尋常物品的巨額捐款有時會抑制我們的熱情。當我們計算數千家上市公司的數字時,我們發現,特定年份中不尋常的項目所帶來的提振通常不會在第二年重演。考慮到這個名字,這並不奇怪。如果SonoScape Medical認爲該捐款不會重演,那麼在其他條件相同的情況下,我們預計其本年度的利潤將下降。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓你想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看根據他們的估計描繪未來盈利能力的交互式圖表。

Our Take On SonoScape Medical's Profit Performance

我們對SonoScape Medical利潤表現的看法

We'd posit that SonoScape Medical's statutory earnings aren't a clean read on ongoing productivity, due to the large unusual item. Because of this, we think that it may be that SonoScape Medical's statutory profits are better than its underlying earnings power. But on the bright side, its earnings per share have grown at an extremely impressive rate over the last three years. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. So while earnings quality is important, it's equally important to consider the risks facing SonoScape Medical at this point in time. At Simply Wall St, we found 1 warning sign for SonoScape Medical and we think they deserve your attention.

我們認爲,由於這個很大的不尋常項目,SonoScape Medical的法定收入並不能完全反映持續的生產力。因此,我們認爲SonoScape Medical的法定利潤可能好於其基礎盈利能力。但好的一面是,其每股收益在過去三年中以極其驚人的速度增長。當然,我們只是在分析其收益時才浮出水面;人們還可以考慮利潤率、預測增長和投資回報率等因素。因此,儘管收益質量很重要,但考慮SonoScape Medical目前面臨的風險同樣重要。在 Simply Wall St,我們發現了 SonoScape Medical 的 1 個警告標誌,我們認爲它們值得你關注。

This note has only looked at a single factor that sheds light on the nature of SonoScape Medical's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

這份報告只研究了揭示SonoScape Medical利潤性質的單一因素。但是,還有很多其他方法可以讓你對公司的看法。有些人認爲高股本回報率是優質業務的好兆頭。因此,你可能希望看到這份擁有高股本回報率的公司的免費集合,或者這份內部所有權高的股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接聯繫我們。或者,也可以發送電子郵件至編輯團隊 (at) simplywallst.com。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論